



SUVEN LIFE SCIENCES LTD

Off:SDE Serene Chambers,6th floor, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2021 & UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2021 .

Rs. In Lakhs

PART - I		STANDALONE				
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended	
		31/03/2021	31/12/2020	31/03/2020	31/03/2021	31/03/2020
		Refer note.9	Un-Audited	Refer note.9	Audited	Audited
		(1)	(2)	(3)	(4)	(5)
1	Income					
	Revenue from operations	155.71	151.30	866.00	1,347.83	1,441.47
	Other Income	132.31	162.41	299.71	775.37	1,403.63
	Total income	288.02	313.71	1,165.71	2,123.20	2,845.10
2	Expenses					
	a) Cost of materials consumed	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	c) Employee benefits expense	321.77	379.91	348.16	1,528.50	1,459.51
	d) Finance costs	24.19	14.19	22.19	81.54	48.71
	e) Depreciation and amortisation expense	106.56	114.11	105.24	434.62	416.87
	f) Manufacturing Expenses	-	-	-	-	-
	g) R & D Expenses	589.96	730.42	576.33	2,517.04	2,594.44
	h) Other Expenses	91.75	80.47	150.27	356.99	919.18
	Total expenses	1,134.23	1,319.10	1,202.19	4,918.69	5,438.71
3	Profit before exceptional items & Tax (1-2)	(846.21)	(1,005.39)	(36.48)	(2,795.49)	(2,593.61)
4	Exceptional Items	-	-	-	-	-
5	Profit before Tax (3-4)	(846.21)	(1,005.39)	(36.48)	(2,795.49)	(2,593.61)
6	Tax Expenses					
	a) Current tax	-	-	197.18	-	197.18
	b) Deferred tax	4.58	(190.68)	22.69	(532.28)	(1,415.47)
7	Net Profit/ (Loss) for the period/year(5-6)	(850.79)	(814.71)	(256.35)	(2,263.21)	(1,375.32)
8	Other Comprehensive Income					
8.a	(i) Items that will not be reclassified to profit or loss	(13.09)	(11.36)	(28.88)	(47.15)	(45.41)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.58	3.97	10.09	16.48	15.87
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income	(8.51)	(7.39)	(18.79)	(30.67)	(29.54)
9	Total Comprehensive Income for the period (7+8)	(859.30)	(822.10)	(275.14)	(2,293.88)	(1,404.86)
10	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity				35,200.64	37,494.53
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :					
	a) Basic	(0.67)	(0.64)	(0.20)	(1.78)	(1.08)
	b) Diluted	(0.67)	(0.64)	(0.20)	(1.78)	(1.08)
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)

PART - I		CONSOLIDATED				
Sl. No.	PARTICULARS	For the Quarter Ended			For the year ended	
		31/03/2021	31/12/2020	31/03/2020	31/03/2021	31/03/2020
		Refer note.9	Un-Audited	Refer note.9	Audited	Audited
		(1)	(2)	(3)	(4)	(5)
1	Income					
	Revenue from operations	155.71	151.30	866.00	1,347.83	1,441.47
	Other Income	132.31	162.41	299.71	775.37	1,403.63
	Total income	288.02	313.71	1,165.71	2,123.20	2,845.10
2	Expenses					
	a) Cost of materials consumed	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	c) Employee benefits expense	417.05	450.14	433.21	1,852.75	1,740.91
	d) Finance costs	24.19	14.19	22.19	81.54	48.71
	e) Depreciation and amortisation expense	106.56	114.11	105.24	434.62	416.87
	f) Manufacturing Expenses	-	-	-	-	-
	g) R & D Expenses	1,795.58	2,273.74	2,783.77	7,102.73	10,322.64
	h) Other Expenses	101.30	91.50	157.25	398.96	956.05
	Total expenses	2,444.68	2,943.68	3,501.66	9,870.60	13,485.18
3	Profit before exceptional items , Tax (1-2)	(2,156.66)	(2,629.97)	(2,335.95)	(7,747.40)	(10,640.08)
4	Exceptional Items- (Ref Note:7)	-	-	-	-	-
5	Profit before Tax (3-4)	(2,156.66)	(2,629.97)	(2,335.95)	(7,747.40)	(10,640.08)
6	Tax Expenses					
	a) Current tax	-	-	197.18	-	197.18
	b) Deferred tax	4.58	(190.68)	22.69	(532.28)	(1,415.47)
7	Net Profit/ (Loss) for the period/year(5-6)	(2,161.24)	(2,439.29)	(2,555.82)	(7,215.12)	(9,421.79)
8	Other Comprehensive Income					
8.a	(i) Items that will not be reclassified to profit or loss	(13.09)	(11.36)	(28.89)	(47.15)	(45.41)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.58	3.97	10.10	16.48	15.87
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total other Comprehensive Income	(8.51)	(7.39)	(18.79)	(30.67)	(29.54)
9	Total Comprehensive Income for the period (7+ 8)	(2,169.75)	(2,446.68)	(2,574.61)	(7,245.79)	(9,451.33)
10	Paid-up equity share capital Face Value of the Share	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00
11	Other Equity	-	-	-	5,835.74	13,062.02
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :					
	a) Basic	(1.70)	(1.92)	(2.01)	(5.67)	(7.40)
	b) Diluted	(1.70)	(1.92)	(2.01)	(5.67)	(7.40)
		(not annualised)	(not annualised)	(not annualised)	(annualised)	(annualised)

NOTES:-

1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 04, 2021. The results for the year ended March 31, 2021 has been audited and for the quarter ended March 31, 2021 has been reviewed by our statutory auditors.

2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc

4) The National Company Law Tribunal, Hyderabad Bench vide its order dated January 06, 2020 has approved the scheme of arrangement for demerger of CRAMS undertaking of the Company to Suven Pharmaceuticals Limited (SPL) with effect from October 01, 2018 (the appointed date). The Scheme became effective from October 01, 2018. Pursuant to the Scheme, all the assets, liabilities, income and expenses of the CRAMS undertaking have been transferred to SPL from the appointed date.

5) Pursuant to a fire accident on April 26, 2020 at Jeedimetla Plant, certain fixed assets and other contents in buildings was damaged. During the year ended March 31, 2021, the company has written off net book value of assets aggregating Rs.2.28 Crores and recognised a minimum insurance claim receivable for equivalent amount.

6) The COVID-19 did not have impact on the business and research operations, which includes our subsidiary, Suven Neurosciences, Inc.

7) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

8) During the year ended 31-03-2021 with the approval of members in EGM held on 20th March'2021, the board has issued 1,81,00,000 share warrants to promoter group on a preferential basis @ ₹ 81.57 per warrant and received 25% of issue price amounting to ₹ 3,692.00 lakhs on 26-03-2021 in accordance with SEBI Regulations.

9) The figures for the current quarter and quarter ended March 31, 2020 are the balancing figures between the audited figures in respect of full financial year ended March 31, 2021 and March 31, 2020, respectively and published year to date figures upto 3rd quarter ended 31st December 2020 and 31st December 2019, respectively, regrouped as necessary.

Place : Hyderabad
Date : May 4, 2021



For SUVEN LIFE SCIENCES LTD

Venkat Jasti

VENKAT JASTI

Chairman & CEO

DIN: 00278028



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034


Statement of Assets & Liabilities

Rs.in Lakhs

Particulars	Standalone as at		Consolidated as at	
	31/03/2021	31/03/2020	31/03/2021	31/03/2020
A ASSETS				
1 Non-current assets				
(a) Property, Plant and Equipment	1,774.48	2,063.88	1,774.48	2,063.88
(b) Capital Work-in-Progress	477.40	-	477.40	-
(c) Other Intangible Assets	13.60	15.13	13.60	15.13
(d) Right of use Assets	308.18	390.36	308.18	390.36
(e) Financial Assets				
I. Investments	29,502.55	24,181.31	-	-
II. Loans	-	9,125.25	-	9,125.25
Total Non-Current assets	32,076.21	35,775.93	2,573.66	11,594.62
2 Current assets				
Inventories	14.15	-	14.15	-
(a) Financial Assets				
I. Investments	8.57	4.94	8.57	4.94
II. Trade Receivables	176.19	227.05	176.19	227.05
III. Cash and Cash equivalents	129.07	70.76	934.82	1,467.57
IV. Bank balances other than (III) above	3,730.12	41.65	3,730.12	41.65
V. Loans	4,144.87	4,200.70	4,144.87	4,200.70
VI. Other Financial assets	-	-	-	2.05
(b) Current Tax asset (net)	534.78	458.10	534.78	458.10
(c) Other current assets	724.64	196.56	724.64	196.56
Total Current assets	9,462.39	5,199.76	10,268.14	6,598.62
TOTAL - ASSETS	41,538.60	40,975.69	12,841.80	18,193.24
B EQUITY AND LIABILITIES				
1 EQUITY				
(a) Equity Share Capital	1,272.82	1,272.82	1,272.82	1,272.82
(b) Warrant pending allotment	3,692.00	-	3,692.00	-
(c) Other Equity	35,200.64	37,494.53	5,835.74	13,062.02
Total Equity	40,165.46	38,767.35	10,800.56	14,334.84
2 LIABILITIES				
(a) Financial Liabilities				
I. Lease Liabilities	232.60	293.50	232.60	293.50
II. Borrowings	39.25	108.49	39.25	108.49
(b) Provisions	172.87	172.06	172.87	172.06
(c) Other non current liabilities	5.56	46.63	5.56	46.63
(d) Deferred tax Liabilities (net)	-	586.60	-	586.60
Total non-current liabilities	450.28	1,207.28	450.28	1,207.28
Current liabilities				
(a) Financial Liabilities				
I. Lease Liabilities	110.11	104.87	110.11	104.87
II. Trade payables				
a) To Micro & Small Enterprises	19.61	28.42	19.61	28.42
b) Other than Micro & Small Enterprises	279.95	549.78	279.95	549.78
III. Other Financial Liabilities	362.55	180.12	1,030.65	1,830.18
(b) Other Current liabilities	72.30	64.57	72.30	64.57
(c) Provision Employee benefits	78.34	73.30	78.34	73.30
Total - Current liabilities	922.86	1,001.06	1,590.96	2,651.12
Total Liabilities	1,373.14	2,208.34	2,041.24	3,858.40
TOTAL - EQUITY AND LIABILITIES	41,538.60	40,975.69	12,841.80	18,193.24

For Suven Life Sciences Ltd

Place: Hyderabad
Date: May 4, 2021




Venkat Jasti
Chairman & CEO

SUVEN LIFE SCIENCES LIMITED

Standalone Statement of Cash flows for the year ended 31st March, 2021

(All amounts in Indian Rupees In Lakhs, unless otherwise stated)

Particulars	For the year ended 31st March 2021	For the year ended 31st March 2020
A. Cash flow from operating activities		
Profit/(Loss) before tax	(2,795.50)	(2,593.61)
Adjustments :		
Depreciation and amortisation expense	352.44	396.33
Interest Income	(697.91)	(1,321.31)
Finance Cost	81.54	48.71
Unrealised/sale of Gain on Current Investment	(6.06)	(50.22)
Operating profit before working capital changes	(3,065.49)	(3,520.10)
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	50.86	37.38
Inventories	(14.15)	-
Other non current assets	82.18	(390.36)
Other current assets	(436.51)	116.83
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	(278.64)	(130.39)
Long term provisions	0.80	23.43
Other non-current liabilities	(41.07)	(29.06)
Short term provision	(42.11)	(35.29)
Other financial liabilities	182.43	(309.86)
Other current liabilities	7.73	0.50
Cash generated from operating activities	(3,553.97)	(4,236.94)
Income taxes paid (net of refunds)	114.52	278.12
Net Cash flows from operating activities	(3,668.49)	(4,515.06)
B. Cash flow from Investing activities		
Payments for Purchase of property, plant and equipment	(630.47)	(238.51)
Other non current financial assets	9,125.25	(9,125.25)
Other current financial assets	55.83	549.12
Interest received	697.91	1,321.31
Changes in Investments	(5,321.24)	(10,544.97)
Sale/(purchase) of mutual funds	2.43	22,237.66
Bank balances not considered as cash and cash equivalents	(3,688.47)	4.13
Net cash flow from /(used in) investing activities	241.23	4,203.49
C. Cash flows from financing activities		
(Repayment)/Proceeds from borrowings	(69.24)	(69.04)
Proceeds from Share Warrants	3,692.00	-
Changes In Lease Liability	(55.66)	398.36
Finance Cost	(81.54)	(54.03)
Net cash flow from /(used In) financing activities	3,485.56	275.29
Net increase/(decrease) in cash and cash equivalents	58.31	69.49
Cash and cash equivalents as at the beginning of the year	70.76	1.27
Cash and cash equivalents at the end of the year	129.07	70.76



For SUVEN LIFE SCIENCES LTD

Venkat Jasti
VENKAT JASTI
 Chairman & CEO
 DIN: 00278028

Place : Hyderabad
 Date : May 4, 2021

SUVEN LIFE SCIENCES LIMITED

Consolidated Statement of Cash flows for the year ended 31st March, 2021

(All amounts in Indian Rupees In Lakhs, unless otherwise stated)

Particulars	For the year ended 31st March 2021	For the year ended 31st March 2020
A. Cash flow from operating activities		
Profit/(Loss) before tax	(7,747.41)	(10,640.08)
Adjustments :		
Depreciation and amortisation expense	352.44	396.33
Interest Income	(697.91)	(1,321.31)
Finance Cost	81.54	48.71
Unrealised/sale of Gain on Current Investment	(6.06)	50.22
Operating profit before working capital changes	(8,017.40)	(11,466.13)
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	50.86	37.38
Inventories	(14.15)	-
Other non current assets	82.18	(390.36)
Other current assets	(436.51)	116.83
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	(278.64)	(130.39)
Long term provisions	0.80	23.43
Other non-current liabilities	(41.07)	(29.06)
Short term provision	(42.11)	(35.29)
Other financial liabilities	(799.53)	(1,306.06)
Other current liabilities	7.73	0.50
Cash generated from operating activities	(9,487.85)	(13,179.17)
Income taxes paid (net of refunds)	114.52	278.12
Net Cash flows from operating activities	(9,602.36)	(13,457.28)
B. Cash flow from Investing activities		
Payments for Purchase of property, plant and equipment	(630.47)	(238.51)
Other non current financial assets	9,125.25	(9,125.25)
Other current financial assets	57.88	548.96
Interest received	697.91	1,321.31
Sale/(purchase) of mutual funds	2.43	22,237.66
Foreign currency translation reserve	19.52	(126.81)
Bank balances not considered as cash and cash equivalents	(3,688.47)	4.13
Net cash flow from /(used in) investing activities	5,584.04	14,621.50
C. Cash flows from financing activities		
(Repayment)/Proceeds from borrowings	(69.24)	(69.04)
Proceeds from Share Warrants	3,692.00	-
Changes In Lease Liability	(55.66)	398.36
Finance Cost	(81.54)	(48.71)
Net cash flow from /(used In) financing activities	3,485.56	280.61
Net increase/(decrease) in cash and cash equivalents	(532.76)	1,444.83
Cash and cash equivalents as at the beginning of the year	1,467.57	22.75
Cash and cash equivalents at the end of the year	934.82	1,467.57



For SUVEN LIFE SCIENCES LTD

Venkat Jasti
VENKAT JASTI
 Chairman & CEO
 DIN: 00278028

Place : Hyderabad
 Date : May 4, 2021